NCT05272878View on ClinicalTrials.gov

Impact of a Treatment With Angiotensin Receptor Blocker on Outcome After Acute Kidney Injury in Patients Discharged From the ICU.

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

508

Participants

Timeline

Start Date

November 22, 2022

Primary Completion Date

June 27, 2025

Study Completion Date

June 27, 2026

Conditions
Acute Kidney Injury
Interventions
DRUG

IRBESARTAN, tablet, 150 mg

IRBESARTAN will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit.Treatment will be continued for 12 months, unless a side effect would occur.

DRUG

Placebo, tablet, 150 mg

Placebo will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit.Treatment will be continued for 12 months, unless a side effect would occur.

Trial Locations (1)

75010

Hospital Lariboisière, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER